Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent (pre-screening consent) prior to any study specific procedures~2. Female and male patients aged ≥18 and ≤ 90 years~3. Provision of informed consent prior to any study specific procedures~4. Two consecutive i-STAT potassium values, measured 60 minutes (± 10 minutes) apart, both ≥ 5.1 mmol/L and measured within 1 day of the first ZS dose on open-label initial phase Day 1~5. Ability to have repeated blood draws or effective venous catheterization~6. Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study (from the time they sign consent) and for 3 months after the last dose of ZS/matching placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used~Exclusion Criteria:~1. Involvement in the planning and/or conduct of the study~2. Participation in another clinical study with an investigational product during the last 3 months~3. Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated~4. Pseudohyperkalemia signs and symptoms, such as hemolyzed blood specimen due to excessive fist clenching to make veins prominent, difficult or traumatic venepuncture, or history of severe leukocytosis or thrombocytosis~5. Patients treated with lactulose, xifaxan (rifaximin) or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug~6. Patients treated with resins,calcium acetate,calcium carbonate, or lanthanum carbonate,within 7 days prior to the first dose of study drug~7. Patients with a life expectancy of less than 3 months~8. Patients who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol~9. Female patients who are pregnant, lactating, or planning to become pregnant~10. Patients with diabetic ketoacidosis~11. Known hypersensitivity or previous anaphylaxis to ZS or to components thereof~12. Patients with cardiac arrhythmias that require immediate treatment~13. History of QT prolongation associated with other medications that required discontinuation of that medication.~14. Congenital long QT syndrome~15. Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted~16. QTc(f) \> 550 msec~17. Patients on dialysis~18. Patients who are blood donors should not donate blood during the study and for 3 months following their last dose of ZS~19. Patients who need hospitalization after taking blood samples on day 1 of the open-label initial phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Zirconium Cyclosilicate 10g (Type: EXPERIMENTAL): Suspension administered 10g orally once daily for 28 days after the open label initial phase.
- Sodium Zirconium Cyclosilicate 5g (Type: EXPERIMENTAL): Suspension administered 5g orally once daily for 28 days after the open label initial phase.
- Matching Placebo (Type: PLACEBO_COMPARATOR): Suspension administered orally placebo once daily for 28 days after the open label initial phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).